Reldesemtiv in Amyotrophic Lateral Sclerosis: Cytokinetics CY 5031

Summary

The purpose of this study is to evaluate the effectiveness and safety of an investigational drug called reldesemtiv in amyotrophic lateral sclerosis (ALS). The study will evaluate patients' muscle strength and breathing, as well as conduct physical assessments and questionnaires. The questionnaires will address quality of life, mood, and ALS function. Blood and urine samples will also be collected. Additionally, researchers will evaluate the pharmacokinetics of reldesemtiv (how much reldesemtiv gets into the blood stream and how long it takes the body to get rid of it). Reldesemtiv is being studied as a potential new therapy for the improvement of skeletal muscle function in conditions associated with muscle weakness or fatigue, such as ALS. Participants will be randomly assigned to receive either reldesemtiv or placebo (inactive substance).


Inclusion Criteria

Not Available


Study Location(s)

Beverly


Full Title

A PHASE 3, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF RELDESEMTIV IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS

Details
Disease Type/Condition

ALS, Amyotrophic lateral sclerosis

Principal Investigator

Lewis, Richard

Co-Investigators

Matthew Burford

Age Group

Adult

Phase

III

IRB Number

STUDY00001329


Contact
Phone
310-423-6252
Email
clinicaltrials@cshs.org
Want to join the study or
learn more?

Details
Disease Type/Condition

ALS, Amyotrophic lateral sclerosis

Principal Investigator

Lewis, Richard

Age Group

Adult

Phase

III

IRB Number

CY5031


Contact
Phone
310-423-6252
Email
clinicaltrials@cshs.org
Want to join the study or
learn more?